Online inquiry

IVTScrip™ pT7-VEE-mRNA-Anti-Canlupfam NGF, NV-01 Vector   (CAT#: GTVCR-WQ2099MR)

This product GTVCR-WQ2099MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the T7 promoter to efficiently generate mRNA ecoding antibody which targeting Canlupfam NGF. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter T7
Resistance Ampicillin
Species Caninized
RefSeq NM_001194950.1
Applications IVT; Self-amplifying mRNA (SAM) research; Gene therapy research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Target Gene
Gene ID 403402
UniProt ID F1PDQ3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pT7-VEE-mRNA-Anti-Canlupfam NGF, NV-01 Vector (GTVCR-WQ2099MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ109MR IVTScrip™ pSP6-VEE-mRNA-Anti-RTN4, 6A3-IgG4 Vector Vector 6A3-IgG4
GTVCR-WQ1525MR IVTScrip™ pSP6-VEE-mRNA-Anti-CD3E&PMEL, IMCgp100 Vector Vector IMCgp100
GTVCR-WQ123MR IVTScrip™ pT7-VEE-mRNA-Anti-IL17A&TNF, A-1230717 Vector Vector A-1230717
GTVCR-WQ1350MR IVTScrip™ pSP6-VEE-mRNA-Anti-F, H1H3592P3 Vector Vector H1H3592P3
GTVCR-WQ549MR IVTScrip™ pSP6-VEE-mRNA-Anti-FCGRT, ARGX-113 Vector Vector ARGX-113
GTVCR-WQ2093MR IVTScrip™ pSP6-VEE-mRNA-Anti-MUC5AC, NOE-102 Vector Vector NOE-102
GTVCR-WQ682MR IVTScrip™ pSP6-VEE-mRNA-Anti-IL23A, BI 655066 Vector Vector BI 655066
GTVCR-WQ2416MR IVTScrip™ pT7-VEE-mRNA-Anti-IGF1R, RO4858696-000 Vector Vector RO4858696-000
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.